Post by frumenti on Jun 17, 2015 12:43:40 GMT -5
"Looking For Diogenes" wrote an article in SA titled "MannKind: A Head Pain Gain Or A Pocket-Book Drain?". First, this an anonymous article.
Second the writer is paid based on the number of people click on article. Third, LFD spent 40 years in publishing. His profile states
no training in medicine or science. He is therefore not qualified to speak on medicine or the science of how drugs work in the
human body. Writers without skill or experience in a field must regurgitate what others say without the knowledge
or experience necessary to form opinions about scientific matters and/or medicine. In his profile he lists his hobbies
as "world travel and reading-and researching stocks he has an in". So we are to believe what he says even though
his research is a hobby. A person works on a hobby when they have time or want to and I can see why he publishes
anonymously. I were him I would not like for anyone to connect me what was said in this SA article either.
He was upset when MNKD had two different opinions at two different times as to when a new API would be ready.
In April of 2015 Edstrom said 12 to 18 months and at GS conference executives said 18 to 24 months.
He wondered why the change in timeline when the FDA approval process is notoriously slow and unpredictable.
This shows he knows nothing about the pharmaceutical industry. He comments raised the specter of evil doings
when delays with the FDA are the very definition of the FDA. The purpose of the FDA is to slow the process so
time is made to check the safety and efficacy of the drug and the time required is unpredictable and subject to
change by the FDA's actions and everyone knows that, who knows anything about the pharmaceutical industry.
Executives in the industry give estimates based on what the company must do to get a drug ready
for market assuming the FDA does not require additional time for compliance and FDA requirements change
often are not predictable.
This article is about the use of Triptan and variations. I find no reference to Triptan on any website or
any documents connected to MNKD. I do find a patent for the use of an Opioid in an inhaler for pain.
Torre Pines is referenced in the patent. So the entire article by "Looking For Diogenes" is trash.
I wait for a response.
Second the writer is paid based on the number of people click on article. Third, LFD spent 40 years in publishing. His profile states
no training in medicine or science. He is therefore not qualified to speak on medicine or the science of how drugs work in the
human body. Writers without skill or experience in a field must regurgitate what others say without the knowledge
or experience necessary to form opinions about scientific matters and/or medicine. In his profile he lists his hobbies
as "world travel and reading-and researching stocks he has an in". So we are to believe what he says even though
his research is a hobby. A person works on a hobby when they have time or want to and I can see why he publishes
anonymously. I were him I would not like for anyone to connect me what was said in this SA article either.
He was upset when MNKD had two different opinions at two different times as to when a new API would be ready.
In April of 2015 Edstrom said 12 to 18 months and at GS conference executives said 18 to 24 months.
He wondered why the change in timeline when the FDA approval process is notoriously slow and unpredictable.
This shows he knows nothing about the pharmaceutical industry. He comments raised the specter of evil doings
when delays with the FDA are the very definition of the FDA. The purpose of the FDA is to slow the process so
time is made to check the safety and efficacy of the drug and the time required is unpredictable and subject to
change by the FDA's actions and everyone knows that, who knows anything about the pharmaceutical industry.
Executives in the industry give estimates based on what the company must do to get a drug ready
for market assuming the FDA does not require additional time for compliance and FDA requirements change
often are not predictable.
This article is about the use of Triptan and variations. I find no reference to Triptan on any website or
any documents connected to MNKD. I do find a patent for the use of an Opioid in an inhaler for pain.
Torre Pines is referenced in the patent. So the entire article by "Looking For Diogenes" is trash.
I wait for a response.
